Literature DB >> 31955299

Treatment of tics associated with Tourette syndrome.

Joseph Jankovic1.   

Abstract

Motor and phonic tics associated with Tourette syndrome (TS) can range in severity from barely perceptible to disabling and most patients have a variety of behavioral co-morbidities, particularly, attention deficit disorder and obsessive compulsive disorder. Therefore, therapy must be tailored to the individual needs of the patients. In addition to behavioral therapy, oral medications such as alpha agonists, dopamine depletors, anti-psychotics, and topiramate are used to control the involuntary movements and noises. Botulinum toxin injections are particularly effective in patients with troublesome focal motor and phonic tics, including coprolalia. Deep brain stimulation may be considered for patients with "malignant" TS, that is, refractory to medical therapy. When appropriate therapy is selected and implemented, most patients with TS can achieve their full potential and lead essentially normal life.

Entities:  

Keywords:  Attention deficit disorder; Botulinum toxin; Deutetrabenazine; Obsessive-compulsive disorder; Tics; Tourette syndrome

Mesh:

Substances:

Year:  2020        PMID: 31955299     DOI: 10.1007/s00702-019-02105-w

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  5 in total

Review 1.  Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments.

Authors:  Andrew Billnitzer; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

2.  Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial.

Authors:  Barbara Coffey; Joseph Jankovic; Daniel O Claassen; Joohi Jimenez-Shahed; Barry J Gertz; Elizabeth A Garofalo; David A Stamler; Maria Wieman; Juha-Matti Savola; Mark Forrest Gordon; Jessica K Alexander; Hadas Barkay; Eran Harary
Journal:  JAMA Netw Open       Date:  2021-10-01

Review 3.  European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.

Authors:  Veit Roessner; Heike Eichele; Jeremy S Stern; Liselotte Skov; Renata Rizzo; Nanette Mol Debes; Péter Nagy; Andrea E Cavanna; Cristiano Termine; Christos Ganos; Alexander Münchau; Natalia Szejko; Danielle Cath; Kirsten R Müller-Vahl; Cara Verdellen; Andreas Hartmann; Aribert Rothenberger; Pieter J Hoekstra; Kerstin J Plessen
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-11-10       Impact factor: 4.785

4.  Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study.

Authors:  Saar Anis; Corinne Zalomek; Amos D Korczyn; Alina Rosenberg; Nir Giladi; Tanya Gurevich
Journal:  Behav Neurol       Date:  2022-03-09       Impact factor: 3.342

5.  Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.

Authors:  Joseph Jankovic; Barbara Coffey; Daniel O Claassen; Joohi Jimenez-Shahed; Barry J Gertz; Elizabeth A Garofalo; David A Stamler; Maria Wieman; Juha-Matti Savola; Mark Forrest Gordon; Jessica Alexander; Hadas Barkay; Eran Harary
Journal:  JAMA Netw Open       Date:  2021-10-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.